Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 19Thyroid Neoplasms 6Glioma 6Thyroid Carcinoma, Anaplastic 5Multiple Myeloma 5Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Thyroid Cancer, Papillary 3Hematologic Neoplasms 3Skin Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Lymphoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Colonic Neoplasms 2Brain Neoplasms 2Astrocytoma 2Adenocarcinoma, Follicular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, follicular 1Thyroid cancer, Hurthle cell 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Differentiated Thyroid Cancer (DTC) × dabrafenib × 1 year × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡